Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy

• Published in: Oncoimmunology 2017-09, Vol.6 (9), p.e1326442-e1326442
• Main Authors: Facciabene, Andrea, De Sanctis, Francesco, Pierini, Stefano, Reis, Edimara S., Balint, Klara, Facciponte, John, Rueter, Jens, Kagabu, Masahiro, Magotti, Paola, Lanitis, Evripidis, DeAngelis, Robert A., Buckanovich, Ronald J., Song, Wenchao C., Lambris, John D., Coukos, George
• Format: Article
• Language: English
• Subjects: C5a; Cancer; complement; endothelium; immunotherapy; Original Research
• ISSN: 2162-4011; 2162-402X; 2162-402X
• DOI: 10.1080/2162402X.2017.1326442

Cancer immunotherapy relies upon the ability of T cells to infiltrate tumors. The endothelium constitutes a barrier between the tumor and effector T cells, and the ability to manipulate local vascular permeability could be translated into effective immunotherapy. Here, we show that in the context of adoptive T cell therapy, antitumor T cells, delivered at high enough doses, can overcome the endothelial barrier and infiltrate tumors, a process that requires local production of C3, complement activation on tumor endothelium and release of C5a. C5a, in turn, acts on endothelial cells promoting the upregulation of adhesion molecules and T-cell homing. Genetic deletion of C3 or the C5a receptor 1 (C5aR1), and pharmacological blockade of C5aR1, impaired the ability of T cells to overcome the endothelial barrier, infiltrate tumors, and control tumor progression in vivo, while genetic chimera mice demonstrated that C3 and C5aR1 expression by tumor stroma, and not leukocytes, governs T cell homing, acting on the local endothelium. In vitro, endothelial C3 and C5a expressions were required for endothelial activation by type 1 cytokines. Our data indicate that effective immunotherapy is a consequence of successful homing of T cells in response to local complement activation, which disrupts the tumor endothelial barrier.